Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Needle Exchange Programs Needed To Prevent Spread Of HIV, Letter To The Editor Says
"Despite making strides in addressing HIV/AIDS, we have not reached all individuals and communities with the full range of prevention tools needed to reverse the epidemic," Jirair Ratevosian, chair of the American Public Health Association International Health Section"s Advocacy and Policy Committee, writes in a Washington Post letter to the editor. Ratevosian continues, "Congress has a chance to help by lifting the ban on federal funding for syringe exchange programs," adding, "Such programs do more than just distribute clean syringes; they link people into the health care system and drug treatment programs." Ratevosian also discussed support of needle exchange programs by several national health organizations and concludes, "It is imperative that effective approaches to preventing HIV be accessible without delay" (Ratevosian, 7/24).
generic viagra online
Drug-Eluting Stents More Effective Than Bare-Metal Stents In Heart Attack Patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after one year.
News of the day
MorphoSys Reports Filing For Phase 1b/2a Trial For Its Lead Program MOR103 In Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the Company has submitted an application for the authorization of a phase 1b/2a clinical study in patients with active rheumatoid arthritis (RA) for its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor. The trial, which will be conducted in multiple centers in several European countries, is expected to enroll 135 patients in total beginning in the second half of 2009. Additionally, the Company today reported positive results from the phase 1 clinical study for MOR103 in healthy volunteers. The results of this study indicate that MOR103 is generally safe and well tolerated at all doses administered.
Mental Health

Cincinnati, Northern Kentucky Religious Groups Join Efforts To Encourage HIV Testing

A Christian-theater troupe and other area religious leaders are participating in HIV testing efforts targeting the black community in Greater Cincinnati and Northern Kentucky as part of National HIV Testing Day, the Cincinnati Enquirer reports. According to the Enquirer, local public health officials have long struggled to encourage blacks and other groups to get tested for HIV. Increased awareness efforts by black religious leaders and national initiatives - such as the "Test One Million" campaign organized by the Black AIDS Institute in Los Angeles - have recently focused attention on HIV/AIDS in the black community, Mamie Harris, founder and executive director of IV-Charis, the lead agency in Cincinnati for the "Test One Million" campaign, said (O"Farrell, Cincinnati Enquirer, 6/23). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009